GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Cyclically Adjusted Revenue per Share

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Cyclically Adjusted Revenue per Share : $21.02 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Taro Pharmaceutical Industries's adjusted revenue per share for the three months ended in Dec. 2023 was $4.181. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $21.02 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Taro Pharmaceutical Industries's average Cyclically Adjusted Revenue Growth Rate was 0.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Taro Pharmaceutical Industries was 19.40% per year. The lowest was 4.80% per year. And the median was 9.70% per year.

As of today (2024-04-28), Taro Pharmaceutical Industries's current stock price is $42.40. Taro Pharmaceutical Industries's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $21.02. Taro Pharmaceutical Industries's Cyclically Adjusted PS Ratio of today is 2.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Taro Pharmaceutical Industries was 12.95. The lowest was 1.15. And the median was 5.86.


Taro Pharmaceutical Industries Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Taro Pharmaceutical Industries's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Cyclically Adjusted Revenue per Share Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.23 18.13 18.90 20.51 21.12

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.85 21.12 21.32 21.30 21.02

Competitive Comparison of Taro Pharmaceutical Industries's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Taro Pharmaceutical Industries's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taro Pharmaceutical Industries's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taro Pharmaceutical Industries's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Taro Pharmaceutical Industries's Cyclically Adjusted PS Ratio falls into.



Taro Pharmaceutical Industries Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Taro Pharmaceutical Industries's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=4.181/129.4194*129.4194
=4.181

Current CPI (Dec. 2023) = 129.4194.

Taro Pharmaceutical Industries Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 4.367 99.695 5.669
201406 3.040 100.560 3.912
201409 5.856 100.428 7.547
201412 5.549 99.070 7.249
201503 5.700 99.621 7.405
201506 5.026 100.684 6.460
201509 4.951 100.392 6.383
201512 6.031 99.792 7.822
201603 6.189 100.470 7.972
201606 5.518 101.688 7.023
201609 5.540 101.861 7.039
201612 5.381 101.863 6.837
201703 4.840 102.862 6.090
201706 3.984 103.349 4.989
201709 4.215 104.136 5.238
201712 3.879 104.011 4.827
201803 4.409 105.290 5.419
201806 3.938 106.317 4.794
201809 4.055 106.507 4.927
201812 4.530 105.998 5.531
201903 4.666 107.251 5.630
201906 4.185 108.070 5.012
201909 4.174 108.329 4.987
201912 3.836 108.420 4.579
202003 4.572 108.902 5.433
202006 3.075 108.767 3.659
202009 3.734 109.815 4.401
202012 3.664 109.897 4.315
202103 3.897 111.754 4.513
202106 3.892 114.631 4.394
202109 3.510 115.734 3.925
202112 3.698 117.630 4.069
202203 3.812 121.301 4.067
202206 4.168 125.017 4.315
202209 3.472 125.227 3.588
202212 3.704 125.222 3.828
202303 3.900 127.348 3.963
202306 4.228 128.729 4.251
202309 3.943 129.860 3.930
202312 4.181 129.419 4.181

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Taro Pharmaceutical Industries  (NYSE:TARO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Taro Pharmaceutical Industries's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=42.40/21.02
=2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Taro Pharmaceutical Industries was 12.95. The lowest was 1.15. And the median was 5.86.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Taro Pharmaceutical Industries Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro to Acquire Alchemee From Galderma

By Business Wire Business Wire 02-22-2022

Taro Launches Specialty Generic Deferiprone Tablets, 500mg in the U.S.

By Business Wire Business Wire 09-28-2020

Taro to Release First Quarter Results on July 27, 2022

By Business Wire Business Wire 07-26-2022

Taro Announces Resignation of Chief Financial Officer

By Business Wire Business Wire 07-14-2021